alexa Antidepressant Tolerability and Potential Clinical Implications of Serotonin-2A Receptor Genotypes | OMICS International | Abstract
ISSN: 2167-065X

Clinical Pharmacology & Biopharmaceutics
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Antidepressant Tolerability and Potential Clinical Implications of Serotonin-2A Receptor Genotypes

James M Stevenson and Jeffrey R Bishop*
Department of Pharmacy Practice, University of Illinois at Chicago College of Pharmacy, Chicago, USA
Corresponding Author : Dr. Jeffrey R Bishop
Department of Pharmacy Practice
University of Illinois at Chicago College of Pharmacy
833 S. Wood St Rm 164 (M/C 886), Chicago, IL 60612, USA
E-mail: [email protected]
Received April 29, 2013; Accepted June 14, 2013; Published June 17, 2013
Citation: Stevenson JM, Bishop JR (2013) Antidepressant Tolerability and Potential Clinical Implications of Serotonin-2A Genotypes. Clin Pharmacol Biopharm 2:109. doi:10.4172/2167-065X.1000109
Copyright: © 2013 Stevenson JM, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Despite the development of new therapeutic agents for the treatment of mood disorders, drug tolerability remains a major barrier to effective treatment for many patients. Pharmacogenomic studies aim to identify genetic markers that moderate drug response and tolerability, with the intention that this information will aid in drug selection and dosing. The serotonin-2A receptor gene (HTR2A) is one attractive candidate gene for pharmacogenomic studies of drugs for mood disorders. Numerous studies have examined associations between polymorphisms within this gene and efficacy and tolerability of drugs for mood disorders. Some of these variants are now being included in some commercially-available platforms with the intent of using them for therapeutic decision making. As these technologies become more widely utilized, clinicians will face decision about what this information means for patients and how/if to apply this information clinically. This review aims to assist clinicians in this task by summarizing pharmacogenomic studies of the association between polymorphisms of HTR2A and tolerability outcomes in a number of adverse drug reaction domains.

Keywords

Recommended Conferences

33rd World Congress on Pharmacology

Barcelona, Spain
Share This Page
Top